1. Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy
- Author
-
Félix Gutiérrez, Javier García-Abellán, Ronald Galdamez, Mar Masiá, Guillermo Telenti, Catalina Robledano, Sergio Padilla, José A. García, Marta Real Fernández, and Vanessa Agullo
- Subjects
0301 basic medicine ,cardiovascular risk ,medicine.medical_specialty ,030106 microbiology ,antiretroviral therapy ,Integrase inhibitor ,Overweight ,INSTI ,Major Articles ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Internal medicine ,medicine ,overweight ,030212 general & internal medicine ,business.industry ,Hazard ratio ,blood pressure ,medicine.disease ,Obesity ,Infectious Diseases ,Blood pressure ,Oncology ,medicine.symptom ,business ,Body mass index ,Weight gain ,metabolism ,dislypidemia - Abstract
Background Integrase strand transfer inhibitors (INSTI) have been associated with weight gain, but their effect on short-term overweight/obesity incidence, blood pressure(BP) and metabolic markers change has not been described in treatment-naïve people with HIV(PWH). Methods Medical records of treatment-naïve persons starting ART at the HIV Clinic of University Hospital of Elche(Spain), between January 2007 and July 2019 were retrospectively reviewed. Standard procedures included measurements of weight, BP and metabolic assessment. Data at baseline, 48, 72, and 96 weeks post ART initiation were analysed. We used Cox mixed-effects model to generate predictions of BMI over time and Generalized Additive Mixed Models(GAMM) to relax the linearity assumptions and generate 95% confidence intervals in the multivariable adjust. Results Among 219 (median age 44.0 years, IQR=37.0-53.5; 46 females) participants. Baseline weight mean(SD) was 70.4(13.7)kg without difference between regimens; 66% had a BMI Conclusions INSTI-based ART was associated in the short-term with a greater risk of overweight/obesity and SBP elevation. Patients developing overweight/obesity increased LDL cholesterol with no other metabolic disturbances.
- Published
- 2019